CSF3 and small cell lung carcinoma: A multicentre, randomised, double-blind, placebo-controlled study investigated the impact of granulocyte colony stimulating factor (G-CSF) as an adjunct to chemotherapy on infection incidence among patients with small-cell lung cancer [12].